NSW2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)

3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)

QLD4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (WITHDRAWN)

WA6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)

NCT06109779

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) (D7025C00001)

3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)

NCT06103864

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) (D7630C00001)

NCT06097728

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

NCT06079879

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea (3543-006)

NCT06079164

A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell Lymphoma (KT-US-656-0601)

NCT06074588

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (2870-004)

NCT06072781

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (RAMP-301)

NCT06047080

A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (GO44145)

NCT06018337

A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

NCT06012435

A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01) (SGNB6A-002)

NCT05999994

CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research

NCT05991388

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

NCT05987332

IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2) (IDE196-002)

NCT05984277

A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC). (eVOLVE-Lung02)

NCT05911295

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater) (SGNDV-001)

NCT05910827

A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers (HMBD-001-103)

3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)

4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)

NCT05891171

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-25)

NCT05870748

REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) (STRO-002-GM3)

NCT05867251

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (AVZO-021-1001)

NCT05818683

A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer (CR109321)

NCT05816252

A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (MK-2870-003--SKB264-II-04)

NCT05800015

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels (R3767-ONC-2236)

NCT05797168

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

NCT05796089

A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer (CHEST-RT)

NCT05789082

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo-170)

NCT05785754

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (DCSZ11-101)

2076 - Wahroonga - Sydney Adventist Hospital (WITHDRAWN)2170 - Liverpool - Liverpool Hospital (COMPLETED)

3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)

4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (WITHDRAWN)

NCT05756322

A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias (LBS-007-CT01)

NCT05676931

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer (EDGE-Lung)

2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)

NCT05671510

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

NSW2200 - Bankstown - Bankstown-Lidcombe Hospital (COMPLETED)2305 - New Lambton Heights - Newcastle Private Hospital (COMPLETED)

QLD4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (COMPLETED)

SA5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)

NCT05668988

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation (DZ2022E0005)

NCT05647122

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors (EGRET)

NCT05633654

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (GS-US-595-6184)

NCT05619913

The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma

NCT05605899

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)

NCT05599984

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors (M23-385)

NCT05566795

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy (DAY101-002)

NCT05555732

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (TERMINATED)

NCT05533775

A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO)

NCT05525247

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors (SLC-3010-001)

NA

NCT05504291

Intravitreal Melphalan for Intraocular Retinoblastoma (ARET2121)

NCT05498428

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer (PALOMA-2)

NCT05462236

A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (AUM001-2001-MK3475-D65)

NCT05453903

A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations (CR109124)

NCT05417594

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

NCT05410145

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (D3S-001-100)

NCT05382299

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 (ASCENT-03)

2060 - North Sydney - Mater Hospital (WITHDRAWN)2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)2640 - Albury - Border Medical Oncology Research Unit (WITHDRAWN)

TAS7000 - Hobart - ICON Cancer Care Hobart (WITHDRAWN)

NCT05359237

A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods (PEPN22P1)

NCT05315700

An Open-Label, Phase 1/2 Study of ORIC-114 As a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (ORIC-114-01)

NCT05304585

A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (ARST2032)

NCT05261399

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).

3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (WITHDRAWN)

NCT05257083

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (CARTITUDE-6)

NCT05254171

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma (ASPIRE)

NSW2485 - Tweed Heads - The Tweed Hospital (WITHDRAWN)

NCT05253651

An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03)

NCT05201547

Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting (DOMENICA)

NCT05183035

A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML (ITCC-101-APAL2020D)

NCT05141149

A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer (PAUF-I)

NCT05139017

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) (2140-003)

NCT05118789

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1) (NVL-520-01)

NCT05094336

A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors (MTAPESTRY-101)

NCT05067283

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (KANDLELIT-001)

NZNZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)

NCT05005299

The VICTORY Study: A Phase I Study of Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

NCT04989803

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (KT-US-499-0150)

NCT04964518

A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS (APG2575AU101)

NCT04956640

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors (LOXO-RAS-20001)

NCT04947189

4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer

NCT04928846

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868)

NCT04920617

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

NCT04895709

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (CA052-002)

NCT04884035

A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (CC-220-DLBCL-001)

NSW2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)

SA5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)

WA6000 - Perth - Royal Perth Hospital (COMPLETED)

NCT04794699

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors (IDE397-001)

NCT04771130

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (BGB-11417-103)

NCT04739670

A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer (BELLA)

NCT04686305

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03) (DL03)

VIC3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)

NCT04684368

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (ACNS2021)

NSW2031 - Randwick - Sydney Children's Hospital (SUSPENDED)2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

VIC3052 - Parkville - Royal Children's Hospital Melbourne (SUSPENDED)

QLD4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT04644068

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

NCT04637763

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (CB10A)

NCT04625907

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04623541

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™-CLL-1)

NCT04614103

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer (IOV-LUN-202)

NCT04612751

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

NCT04516447

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer (ZN-c3-002)

NCT04442022

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) (2020-000605-84--XPORT-DLBCL-030)

NCT04332822

R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (POLAR-BEAR)

NCT04293562

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (AAML1831)

NSW2031 - Randwick - Sydney Children's Hospital (SUSPENDED)2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

QLD4101 - South Brisbane - Queensland Children's Hospital (SUSPENDED)

NCT04221035

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

WA6009 - Perth - Perth Children's Hospital (SUSPENDED)

NCT04185883

A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

WA6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (TERMINATED)

NCT04164199

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (BGB-A317-290-LTE1)

NCT04106492

A Multicenter Phase 1/2a, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors (SQ3370-001)

NCT04031677

A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) (STRASS2)

NCT03970447

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM-AGILE)

NCT03959085

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (AALL1732)

2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)

SA5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)

NCT03947385

A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (IDE196-001)

NCT03850574

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) (TUSCANY)

NCT03666000

Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (PBCAR0191-01)

NCT03522064

High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer (HiTeCH)

NCT03424005

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (Morpheus-panBC)

NCT03165734

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)

NCT02861573

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

NCT02724163

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy (Myechild01)

NCT02670564

Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) (NZ-2015-069--ZH-2014-0535)

NCT02582697

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)

3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)

NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)

ACTRN12625000673448

Detection of Ultra-High Risk Large B-Cell Lymphoma for Early Delivery of Axicabtagene Ciloleucel: A therapeutic arm of the ALLG NHL34 CLARIFY study (ALLG-NHL34-DA)

ACTRN12625000583448

Total Neoadjuvant Therapy for Organ Preservation in Early-Stage Low Rectal Cancer: The EARLY-TNT Trial (EARLY-TNT-Trial)

ACTRN12624001484538

Phase 2 Trial examining IMMUNE-12 for patients with Glioblastoma Multiforme (GBM). (GBMI12)

ACTRN12624001342505

Not Applicable

A Prospective, Open-Label, Randomized, Controlled Post-Market Clinical Trial Investigating the Safety and Effectiveness of Human Amnion Membrane (AM) in a Cohort of Patients with Loss of Full Thickness Skin Graft Following Reconstruction of a Cutaneous Nasal Defect Secondary to Skin Cancer Resection.

ACTRN12624001340527

A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer (PaxPlus-ABC)

ACTRN12624001230549

An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.

ACTRN12624001188527

G-DISCO: A Phase 1 study of feasibility, safety and tolerability of synchronous intravesical administration of gemcitabine and docetaxel - ANZUP 2403.

ACTRN12624001142527

Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (nil)

ACTRN12624000911594

CICAFU Trial: Randomised, controlled trial of CICAPLAST Baume B5+ versus standard of care on tolerability and observance of topical 5% 5-fluorouracil in Patients diagnosed with Actinic Keratoses (AK)

ACTRN12624000738527

AMLM22/D4: The International AML Platform Consortium (IAPC) trial – is a randomised, 2-arm trial that will investigate the efficacy of oral Azacitidine combined with an allogeneic dendritic cell vaccine vididencel, compared with oral Azacitidine alone, in maintaining or inducing negativity for measurable residual disease (MRD) in AML patients in first complete remission (CR1) following intensive chemotherapy. (AMLM22-D4-CADENCE)

ACTRN12624000532505

International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (INTER-EWING-1)

ACTRN12624000110583

Not Applicable

SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (SOCRATES-PILOT)

ACTRN12624000065594

Not Applicable

ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain

ACTRN12624000006549

AMLM26/T3- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - LDAC + Venetoclax (AMLM26-T3-INTERCEPT)

ACTRN12624000005550

Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (NeoFOL-R)

ACTRN12623001301651

Not Applicable

GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients (GeneScreen-5-FU)

ACTRN12623001126606

Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme (TCaP)

ACTRN12623001072606

A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC) (LuCape)

ACTRN12623000900617

Not Applicable

AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (ALLG)

ACTRN12623000874617

Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (Biomarcer-2)

ACTRN12623000657628

BCT 2301 (OLIO): A phase II, randomised, non-comparative two-arm trial of neoadjuvant chemotherapy plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer

ACTRN12623000620628

NHL38 Epco-Sandwich: A phase II multicentre, single arm, open-label trial of epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and epcoritamab consolidation in patients with relapsed large B-cell lymphoma.

ACTRN12623000223639

A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC) (iLSTA)

ACTRN12623000174684

A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer (APG2449OG101)

ACTRN12623000104651

Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours (DART)

ACTRN12622001514796

Not Applicable

KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme

ACTRN12622001366741

Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial

ACTRN12622001232729

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (The-ANZHIT-2-study)

ACTRN12622001201763

Efficacy of Treatment Targeting the Renin-Angiotensin System in Glioblastoma (TRAS-GB) Trial

ACTRN12622000973718

SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation

ACTRN12622000675729

Not Applicable

A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma (LEVI’S-CATCH)

ACTRN12622000308796

A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (VICTORY-study)

ACTRN12622000302752

Not Applicable

Impact of intra-tumour injection of OncoSil (32P) on vascularity, stromal integrity and response to chemotherapy in locally advanced pancreatic carcinoma (none)

ACTRN12622000180718

Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (SPACE-FLOT): An international multicentre cohort study

ACTRN12622000016730

Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (HER2Pro-1B)

ACTRN12621001529831

NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (PACIFIC)

ACTRN12621001265864

AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine (AMLM26-T5)

ACTRN12621000802808

A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults. (LU-TEMP)

ACTRN12621000762853

Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy

ACTRN12621000273886

The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial

ACTRN12621000223831

Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (PREACH-M-(PREACH-M)

ACTRN12620001229965

A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas (TiNT)

ACTRN12620001198910

Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (MODERN-LUNG)

ACTRN12619001656123

Clarifying the role of early application of CAR T cells in Primary refractory and early relapsed diffuse large B cell lymphoma patients. (CLARIFY-NHL34)

ACTRN12619001655134

AMLM25: An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia

ACTRN12619001298101

A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas (ASN-002-IL)

ACTRN12619000566134

OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

ACTRN12619000280101

AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC). (AMLM22-D2)

ACTRN12619000079145

A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The-AutoCAR19-Trial)

ACTRN12617001571369

Effect of Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy on survival rates: SUPER trial.

ACTRN12616000554460

ACES: Adjuvant Chemotherapy in Early stage oeSophageal cancer- a feasibility study

ACTRN12615000647538

Evaluating the efficacy of SIR-spheres in combination with chemotherapy for patients with pancreatic cancer with liver metastases (nil)

ACTRN12614000552684

A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant Neuroblastoma (The-TIO-Study)

ACTRN12613000358741

The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.

NCT06614192

AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer (M24-064)

NCT06509906

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (MS202650-0001)

NCT05852691

A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (CO44194)

NCT04822961

A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment (IMP4297-202)

NCT03170960

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (XL184-021)

NCT02948543

Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial (BCG+MM)

ACTRN12621000991819

Not Applicable

A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (PDCCiHNC)

ACTRN12617001190392

An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer (PIT-Study)

PD-1/PD-L1	30%
PD-1	24%
PD-L1	10%
Trop2	9%
EGFR	9%
VEGF	8%
ERBB2	8%
CD20	8%
Bcl2	7%
DNA methyltransferase	7%
TIGIT	5%
PARP	5%
KRAS	4%
KRAS G12C	4%
androgen axis	4%
CYP17A1	4%
MET	4%
cereblon	4%
CD19	4%
AR	3%
KIT	3%
CTLA4	3%
CDK4	3%
CDK6	3%
ROS1	3%
oestrogen axis	2%
ALK	2%
RET	2%
PDGFR	2%
VEGFR	2%
PI3Kalpha	2%
proteasome	2%
LAG3	2%
RAF	2%
MEK	2%
mTOR	2%
mTORC1	2%
PI3K delta	2%
ER	2%
CD38	2%
FLT3	2%
BRAF	2%
CRAF	2%
DPD	2%
orotate phosphoribosyltransferase	2%
PI3K	2%
mTORC2	2%
VEGFR2	2%
PARP1-selective	2%
BTK	1%
VEGFA	1%
IDH1	1%
IDH1 R132	1%
FR-alpha	1%
pan-RAF	1%
PRMT5	1%
HRAS G12C	1%
NRAS G12C	1%
AXL	1%
JAK1	1%
JAK2	1%
CD79b	1%
PKC	1%
IL-6	1%
CD33	1%
FGFR	1%
FGFR1	1%
FGFR1/2/3	1%
FGFR2	1%
FGFR3	1%
FGFR4	1%
GD2	1%
ERBB3	1%
B7H3	1%
GPRC5D	1%
CD73	1%
BCMA	1%
LSD1	1%
FAK	1%
TIM3	1%
XPO1	1%
STEAP1	0%
fucosyl-GM1	0%
EZH2	0%
TF	0%
ISR	0%
multikinase	0%
CYP11A1	0%
GRPR	0%
GARP	0%
Nectin-4	0%
CLDN18.2	0%
DLL3	0%
ITGB6	0%
CD39	0%
CDK2	0%
KLK2	0%
CD93	0%
gp100	0%
CDC7	0%
SEZ6	0%
MNK	0%
KMT2A	0%
ROR1	0%
CCR8	0%
MAT2A	0%
WEE1	0%
SHP2	0%
HPK1	0%
OX40	0%
VEGFR1	0%
VEGFR3	0%
CD22	0%
AKT	0%
CD40	0%
LIV1	0%
HIF2a	0%
HMG-CoA reductase	0%
PSMA	0%
COX2	0%
GM-CSF	0%
HDAC	0%
JAK	0%
SYK	0%
PDE4	0%
ATR	0%
BCR-ABL1	0%
PDGFRA	0%
SMO	0%
SRC	0%
YES1	0%

ARTICANZ - Beta (ver 0.91)

Search results

target/cytotoxic-chemotherapy

Filters